Key result
This is a protocol for a randomized, double-blind, crossover trial to evaluate the effect of Qishen Taohong granules and TCM external treatment on NYHA class in 82 patients with chronic heart failure.
Why the study?
Chronic heart failure carries high mortality and incidence, and this study aims to evaluate the safety and validity of a TCM comprehensive intervention program in patients with CHF.
Does a Traditional Chinese Medicine comprehensive intervention improve NYHA classification in patients with chronic heart failure?
RCT (n=82)
double-blinded
randomized
No
Does a Traditional Chinese Medicine comprehensive intervention improve NYHA classification in patients with chronic heart failure?
This study protocol outlines a randomized crossover trial to evaluate the efficacy and safety of a comprehensive Traditional Chinese Medicine intervention in patients with chronic heart failure.
Answers are grounded in this paper and cite their sources.
TCM for chronic HF should not yet change practice; this RCT protocol leaves open its effect on NYHA class.
Background. It is known to all the doctors and patients that both the morality and incidence rate of chronic heart failure (CHF) are quite high among various heart diseases. Traditional Chinese medicine (TCM) comprehensive intervention becomes a rising prospective therapy for patients with CHF. Considering the efficacy of TCM, the study aims to test the safety as well as the validity of TCM comprehensive intervention in patients who are struggling with CHF. Methods. The study is an essentially randomized, single-central, placebo-controlled, double-blinded crossover trial. Eighty-two eligible subjects aged 18–75 years with CHF are supposed to be recruited. According to the subject plan, all the patients will be divided into group A and B. The patients in group A will receive oral Qishen Taohong granules (QTGs) combined with TCM external treatment and standard Western medicine for four weeks. After that, a 2-week washout would be proceeded; this group will be reallocated to another four weeks with oral placebo granules combined with TCM external treatment and standard Western medicine. In contrast, group B will perform the opposite protocol. The primary outcome conforms to the classification from the New York Heart Association (NYHA). Meanwhile, the secondary outcomes are echocardiogram, N-terminal pro-B-type natriuretic peptide (NT-proBNP), Chronic Heart Failure Quality of Life Scale of Integrated Chinese and Western Medicine (CHFQLS), TCM syndrome, symptom, sign, six-minute walk test (6MWT), Pittsburgh Sleep Quality Index (PSQI), Montreal cognitive assessment (MoCA), major adverse cardiovascular events (MACEs), and metabolomics. Discussion. Based on conventional treatments, TCM comprehensive intervention may further improve the patients’ cardiac function and then enhance their quality of life. The results will provide high-quality evidence of TCM comprehensive intervention in treating CHF.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted an RCT in chronic heart failure (CHF) (n=82). Qishen Taohong granules (QTGs) combined with TCM external treatment and standard Western medicine vs. placebo granules combined with TCM external treatment and standard Western medicine was evaluated on New York Heart Association (NYHA) classification. This is a protocol for a randomized, double-blind, crossover trial to evaluate the effect of Qishen Taohong granules and TCM external treatment on NYHA class in 82 patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: